These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 34204237)

  • 1. Potential and Limits of Cannabinoids in Alzheimer's Disease Therapy.
    Abate G; Uberti D; Tambaro S
    Biology (Basel); 2021 Jun; 10(6):. PubMed ID: 34204237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocannabinoid System: A Multi-Facet Therapeutic Target.
    Kaur R; Ambwani SR; Singh S
    Curr Clin Pharmacol; 2016; 11(2):110-7. PubMed ID: 27086601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents.
    Murillo-Rodriguez E; Pastrana-Trejo JC; Salas-Crisóstomo M; de-la-Cruz M
    CNS Neurol Disord Drug Targets; 2017; 16(4):370-379. PubMed ID: 28240187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic properties of multi-cannabinoid treatment strategies for Alzheimer's disease.
    Coles M; Steiner-Lim GZ; Karl T
    Front Neurosci; 2022; 16():962922. PubMed ID: 36117622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.
    Ramírez BG; Blázquez C; Gómez del Pulgar T; Guzmán M; de Ceballos ML
    J Neurosci; 2005 Feb; 25(8):1904-13. PubMed ID: 15728830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral effects of cannabinoid agents in animals.
    Chaperon F; Thiébot MH
    Crit Rev Neurobiol; 1999; 13(3):243-81. PubMed ID: 10803637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson's and Alzheimer's Diseases: a Review.
    Cooray R; Gupta V; Suphioglu C
    Mol Neurobiol; 2020 Nov; 57(11):4878-4890. PubMed ID: 32813239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the Cannabinoid System in Alzheimer's Disease.
    Li S; Huang Y; Yu L; Ji X; Wu J
    Curr Neuropharmacol; 2023; 21(3):715-726. PubMed ID: 35105293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.
    Rosenberg EC; Patra PH; Whalley BJ
    Epilepsy Behav; 2017 May; 70(Pt B):319-327. PubMed ID: 28190698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's disease; taking the edge off with cannabinoids?
    Campbell VA; Gowran A
    Br J Pharmacol; 2007 Nov; 152(5):655-62. PubMed ID: 17828287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioral and psychological symptoms of dementia (BPSD) and impaired cognition reflect unsuccessful neuronal compensation in the pre-plaque stage and serve as early markers for Alzheimer's disease in the APP23 mouse model.
    Pfeffer A; Munder T; Schreyer S; Klein C; Rasińska J; Winter Y; Steiner B
    Behav Brain Res; 2018 Jul; 347():300-313. PubMed ID: 29572105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice.
    Aso E; Sánchez-Pla A; Vegas-Lozano E; Maldonado R; Ferrer I
    J Alzheimers Dis; 2015; 43(3):977-91. PubMed ID: 25125475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contrasting protective effects of cannabinoids against oxidative stress and amyloid-β evoked neurotoxicity in vitro.
    Harvey BS; Ohlsson KS; Mååg JL; Musgrave IF; Smid SD
    Neurotoxicology; 2012 Jan; 33(1):138-46. PubMed ID: 22233683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabis and Neuropsychiatric Disorders: An Updated Review.
    Chayasirisobhon S
    Acta Neurol Taiwan; 2019 Jun; 28(2)():27-39. PubMed ID: 31867704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer's disease.
    Bedse G; Romano A; Lavecchia AM; Cassano T; Gaetani S
    J Alzheimers Dis; 2015; 43(4):1115-36. PubMed ID: 25147120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic.
    Aso E; Ferrer I
    Front Pharmacol; 2014; 5():37. PubMed ID: 24634659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of cannabinoids on the brain.
    Ameri A
    Prog Neurobiol; 1999 Jul; 58(4):315-48. PubMed ID: 10368032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of the Cannabinoid System: A New Perspective for the Treatment of the Alzheimer's Disease.
    Talarico G; Trebbastoni A; Bruno G; de Lena C
    Curr Neuropharmacol; 2019; 17(2):176-183. PubMed ID: 29962346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabis and the exocannabinoid and endocannabinoid systems. Their use and controversies.
    Millán-Guerrero RO; Isais-Millán S
    Gac Med Mex; 2019; 155(5):471-474. PubMed ID: 32091020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The therapeutic potential of the endocannabinoid system for Alzheimer's disease.
    Karl T; Cheng D; Garner B; Arnold JC
    Expert Opin Ther Targets; 2012 Apr; 16(4):407-20. PubMed ID: 22448595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.